Dacomitinib (PF299804)
![]() |
- ₹5000 - ₹14200
- Product name: Dacomitinib (PF299804)
- CAS: 1110813-31-4
- MF: C24H25ClFN5O2
- MW: 469.94
- EINECS:-0
- MDL Number:MFCD19443734
- Synonyms:PF-00299804-03;PF-00299804;DacoMitinib (PF-00299804);DacoMitinib,PF299804;DacoMitinib (PF299804,PF-00299804);PF299804;DACOMITINIB;DacoMitinib (PF299804, PF299);(E)-N-(4-((3-chloro-4-fluorophenyl)aMino)-7-Methoxyquizolin-6-yl)-4-(piperidin-1-yl)but-2-eMide
2 prices
Selected condition:
Brand
- TCI Chemicals (India)
Package
- 50MG
- 250MG
- ManufacturerTCI Chemicals (India)
- Product numberD5450
- Product descriptionDacomitinib
- Packaging50MG
- Price₹5000
- Updated2022-05-26
- Buy
- ManufacturerTCI Chemicals (India)
- Product numberD5450
- Product descriptionDacomitinib
- Packaging250MG
- Price₹14200
- Updated2022-05-26
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
TCI Chemicals (India) | D5450 | Dacomitinib | 50MG | ₹5000 | 2022-05-26 | Buy |
TCI Chemicals (India) | D5450 | Dacomitinib | 250MG | ₹14200 | 2022-05-26 | Buy |
Properties
Melting point :184-187°C
Boiling point :665.7±55.0 °C(Predicted)
Density :1.344
storage temp. :Refrigerator
solubility :DMSO (Slightly), Methanol (Slightly, Heated)
form :White solid.
pka :12.05±0.43(Predicted)
color :White to Pale Yellow
CAS DataBase Reference :1110813-31-4
Boiling point :665.7±55.0 °C(Predicted)
Density :1.344
storage temp. :Refrigerator
solubility :DMSO (Slightly), Methanol (Slightly, Heated)
form :White solid.
pka :12.05±0.43(Predicted)
color :White to Pale Yellow
CAS DataBase Reference :1110813-31-4
Safety Information
Symbol(GHS): |
![]() |
||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal word: | Warning | ||||||||||||||
Hazard statements: |
|
||||||||||||||
Precautionary statements: |
|
Description
Dacomitinib is a selective and irreversible inhibitor of EGFR. It is a drug candidate for the treatment of non-small cell lung carcinoma. It is current under the Phase III clinical trials. It also shows potential for the treatment of HER-2 amplified breast cancer cells lines that are resistant to trastuzumab and lapatinib.Related product price
- Dasatinib
₹3702.15-4546.5 - 302964-24-5
₹3300-8800 - Gefitinib
₹4200-45778.93